"""So it sounds like the expected September 2019 BETonMACE top-line data announcement will just be a statement of whether or not BETonMACE met its primary endpoint with statistical significance. """

So, initially, that leaves us with the catastrophic downside of a failed trial, but not very much of the upside of a successful one.

Maybe RVX's press release will give us a clue. If they are "extremely pleased" to report the result, then we may have something along the lines of AMRN. If they are just "pleased", then sell everything immediately.